Logo image of JNCE

JOUNCE THERAPEUTICS INC (JNCE) Stock Fundamental Analysis

NASDAQ:JNCE - Nasdaq - US4811161011 - Common Stock - Currency: USD

1.88  -0.05 (-2.59%)

After market: 1.92 +0.04 (+2.13%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to JNCE. JNCE was compared to 556 industry peers in the Biotechnology industry. While JNCE has a great health rating, there are worries on its profitability. JNCE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year JNCE has reported negative net income.
JNCE had a negative operating cash flow in the past year.
In the past 5 years JNCE reported 4 times negative net income.
JNCE had a negative operating cash flow in each of the past 5 years.
JNCE Yearly Net Income VS EBIT VS OCF VS FCFJNCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M -100M 150M

1.2 Ratios

JNCE has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JNCE Yearly ROA, ROE, ROICJNCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 20 -20 -40 -60 -80

1.3 Margins

JNCE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JNCE Yearly Profit, Operating, Gross MarginsJNCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

More info and screens

7

2. Health

2.1 Basic Checks

JNCE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for JNCE has been increased compared to 1 year ago.
JNCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
JNCE Yearly Shares OutstandingJNCE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
JNCE Yearly Total Debt VS Total AssetsJNCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of 0.64, we must say that JNCE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of JNCE (0.64) is better than 60.92% of its industry peers.
JNCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.64
ROIC/WACCN/A
WACC8.03%
JNCE Yearly LT Debt VS Equity VS FCFJNCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 8.37 indicates that JNCE has no problem at all paying its short term obligations.
JNCE's Current ratio of 8.37 is fine compared to the rest of the industry. JNCE outperforms 68.35% of its industry peers.
JNCE has a Quick Ratio of 8.37. This indicates that JNCE is financially healthy and has no problem in meeting its short term obligations.
JNCE's Quick ratio of 8.37 is fine compared to the rest of the industry. JNCE outperforms 68.35% of its industry peers.
Industry RankSector Rank
Current Ratio 8.37
Quick Ratio 8.37
JNCE Yearly Current Assets VS Current LiabilitesJNCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

JNCE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.20%, which is quite impressive.
Looking at the last year, JNCE shows a very strong growth in Revenue. The Revenue has grown by 205.20%.
JNCE shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.75% yearly.
EPS 1Y (TTM)46.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%266.1%
Revenue 1Y (TTM)205.2%
Revenue growth 3Y-17.85%
Revenue growth 5Y2.75%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, JNCE will show a small growth in Earnings Per Share. The EPS will grow by 6.92% on average per year.
The Revenue is expected to grow by 48.27% on average over the next years. This is a very strong growth
EPS Next Y-37.55%
EPS Next 2Y-3.02%
EPS Next 3Y-8.36%
EPS Next 5Y6.92%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y36.37%
Revenue Next 5Y48.27%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JNCE Yearly Revenue VS EstimatesJNCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
JNCE Yearly EPS VS EstimatesJNCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

JNCE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JNCE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JNCE Price Earnings VS Forward Price EarningsJNCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JNCE Per share dataJNCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as JNCE's earnings are expected to decrease with -8.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.02%
EPS Next 3Y-8.36%

More info and screens

0

5. Dividend

5.1 Amount

JNCE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JOUNCE THERAPEUTICS INC

NASDAQ:JNCE (5/3/2023, 8:26:07 PM)

After market: 1.92 +0.04 (+2.13%)

1.88

-0.05 (-2.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-10 2023-05-10
Earnings (Next)08-02 2023-08-02
Inst Owners0%
Inst Owner Change0%
Ins Owners21.72%
Ins Owner Change0%
Market Cap98.95M
Analysts80
Price Target1.65 (-12.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)901.63%
Min EPS beat(2)7.85%
Max EPS beat(2)1795.4%
EPS beat(4)3
Avg EPS beat(4)446.56%
Min EPS beat(4)-22.76%
Max EPS beat(4)1795.4%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)96.08%
Min Revenue beat(2)96.08%
Max Revenue beat(2)96.08%
Revenue beat(4)1
Avg Revenue beat(4)-34.64%
Min Revenue beat(4)-100%
Max Revenue beat(4)96.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-73.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-17.15%
EPS NY rev (1m)28.8%
EPS NY rev (3m)38.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.21
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.54
EV/EBITDA N/A
EPS(TTM)-0.99
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS1.56
BVpS3.48
TBVpS3.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.03%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.37
Quick Ratio 8.37
Altman-Z 0.64
F-Score3
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)20.06%
Cap/Depr(5y)24.53%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%266.1%
EPS Next Y-37.55%
EPS Next 2Y-3.02%
EPS Next 3Y-8.36%
EPS Next 5Y6.92%
Revenue 1Y (TTM)205.2%
Revenue growth 3Y-17.85%
Revenue growth 5Y2.75%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y36.37%
Revenue Next 5Y48.27%
EBIT growth 1Y42.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.41%
OCF growth 3YN/A
OCF growth 5YN/A